<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04792333</url>
  </required_header>
  <id_info>
    <org_study_id>QGC001-1QG4</org_study_id>
    <secondary_id>2019-001817-18</secondary_id>
    <nct_id>NCT04792333</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics in End Stage Renal Disease Patients</brief_title>
  <official_title>A Phase I Study to Compare Pharmacokinetic Parameters of Firibastat and Its Metabolites (EC33 and QGC515) in Healthy Subjects Versus End Stage Renal Disease (ESRD) Patients After a Single Oral Administration of Firibastat 500 mg</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Quantum Genomics SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eurofins Optimed</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Quantum Genomics SA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is a multicentre, open label, phase I, two arms study to compare pharmacokinetic of&#xD;
      firibastat after a single oral dose of firibastat 500 mg in fourteen healthy male volunteers&#xD;
      and in fourteen End Stage Renal Disease (ESRD) patients not yet in dialysis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It is planned to enroll a total of 28 subjects to receive a single oral dose of&#xD;
      investigational medicinal product (IMP): 14 ESRD patients will be enrolled in three Hungarian&#xD;
      centres (1st arm) and 14 Healthy volunteers will be enrolled by Eurofins Optimed in Gières,&#xD;
      France (2nd arm).&#xD;
&#xD;
      Subjects will be screened for eligibility to participate in the study up to 21 days prior to&#xD;
      the first administration. For both arm, subjects will be admitted into the Clinical Research&#xD;
      Unit (CRU) on Day -3. On the morning of Day 1, subjects will receive a single 500 mg oral&#xD;
      dose of firibastat following an overnight fast (i.e., at least 10 hours). Subjects will be&#xD;
      confined to the CRU until discharge on Day 3 with PK blood sample draws for measurement of&#xD;
      firibastat and its main metabolites being taken throughout the confinement.&#xD;
&#xD;
      A follow-up post study visit will occur on Day 10 post-dose to ensure the ongoing wellbeing&#xD;
      of the subjects.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 17, 2019</start_date>
  <completion_date type="Actual">July 10, 2020</completion_date>
  <primary_completion_date type="Actual">July 10, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Firibastat and metabolites Concentrations</measure>
    <time_frame>Day 1 to Day 3</time_frame>
    <description>The plasma concentration data for firibastat (QGC001), EC33 and QGC515, will be analysed at each time measurement (predose, 0, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 36, 48 hours post-dose)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Systolic and Diastolic Blood Pressure (mmHg)</measure>
    <time_frame>Day 1 to Day 3</time_frame>
    <description>Systolic and Diastolic blood pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart Rate (bpm)</measure>
    <time_frame>Day 1 to Day 3</time_frame>
    <description>number of beats per minute</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hematology blood sample laboratory tests aggregated as number of patients outside ranges</measure>
    <time_frame>Day 1 to Day 3</time_frame>
    <description>Hemoglobin, Hematocrit, MCH, MCHC, MCV, MPV, RBC (erythrocytes), WBC (Leucocytes), Differential Count (Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Large Unstained cells), Platelets.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biochemistry blood sample laboratory tests aggregated as number of patients outside ranges</measure>
    <time_frame>Day 1 to Day 3</time_frame>
    <description>Albumin, Alkaline Phosphatase, ALT, Amylase, AST, Bicarbonate, Bilirubin (direct, indirect and total), Calcium, Chloride, Cholesterol, Creatinine Kinase, Creatinine, gammaGT, HDLcholesterol, LDH, LDL - cholesterol, Lipase, Magnesium, Phosphate, Potassium, Protein total, Sodium, Triglycerides, Urea, Uric Acid, Glucose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemostasis blood sample laboratory tests aggregated as number of patients outside ranges</measure>
    <time_frame>Day 1 to Day 3</time_frame>
    <description>INR, PT, aPTT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinalysis tests aggregated as number of patients outside ranges</measure>
    <time_frame>Day 1 to Day 3</time_frame>
    <description>pH, ketone bodies, proteins, glucose, occult blood, blood leukocytes, nitrite, bilirubin, urobilinogen, density.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Healthy Volunteers</condition>
  <condition>Renal Failure</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>500 mg (2 capsules of 250 mg)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>firibastat</intervention_name>
    <description>Single oral dose of 500 mg administration on Day 1</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>QGC001</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male subjects, aged 18 to 55 years inclusive;&#xD;
&#xD;
          -  Non-smoker subject or smoker of not more than 5 cigarettes a day;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Positive Hepatitis B surface (HBs) antigen or anti Hepatitis C Virus (HCV) antibody,&#xD;
             or positive results for Human Immunodeficiency Virus (HIV) 1 or 2 tests);&#xD;
&#xD;
          -  History or presence of drug or alcohol abuse (alcohol consumption &gt; 40 grams/day);&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yves DONAZZOLO, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Eurofins Optimed</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Eurofins Optimed</name>
      <address>
        <city>Gières</city>
        <zip>38610</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>December 26, 2019</study_first_submitted>
  <study_first_submitted_qc>March 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 10, 2021</study_first_posted>
  <last_update_submitted>March 9, 2021</last_update_submitted>
  <last_update_submitted_qc>March 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Firibastat</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

